HyperlipidemiasHyperlipidemia, Familial CombinedHypolipidemic AgentsTriglyceridesXanthomatosisPeriarthritisCholesterolLipidsCholesterol, LDLAnticholesteremic AgentsHypercholesterolemiaLipoproteinsHydroxymethylglutaryl-CoA Reductase InhibitorsCholesterol, HDLFenofibrateHyperlipoproteinemia Type IIRisk FactorsAzetidinesDiabetes MellitusSimvastatinHypertensionApolipoproteins BLipoproteins, VLDLCardiovascular DiseasesObesityLipoproteins, LDLDiabetes Mellitus, Type 2MalaysiaCoronary DiseaseDiabetes ComplicationsBlood GlucosePrevalenceTendinopathyTerminology as TopicArthritisTreatment OutcomeHypertriglyceridemiaProspective StudiesRegression AnalysisMyocardial InfarctionCase-Control StudiesInsulinKidney TransplantationHyperlipoproteinemia Type IVBody Mass IndexAge FactorsApolipoproteins EPractice Guidelines as TopicLipid MetabolismBiological MarkersApolipoproteins CDrug Therapy, CombinationDouble-Blind MethodApolipoprotein E2Follow-Up StudiesApolipoprotein C-IIILipoprotein LipaseCross-Sectional StudiesSmokingArteriosclerosisLiverApolipoproteinsCholesterol, VLDLGynostemmaReceptors, LDLDietary FatsAtherosclerosisHyperlipoproteinemia Type IIIPoloxamerHeptanoic AcidsDiet, AtherogenicApolipoprotein A-IInsulin ResistanceMice, Inbred C57BLCholesterol, DietaryDyslipidemiasMetabolic Syndrome XPostprandial PeriodFatty LiverBezafibrateEpichlorohydrinTime FactorsBody WeightApolipoproteins AHyperlipoproteinemiasUnited StatesPhenotypeDisease Models, AnimalRetrospective StudiesPyrrolesNephrotic SyndromeHyperlipoproteinemia Type VHyperglycemiaMice, KnockoutApolipoprotein E3Fatty Acids, NonesterifiedGemfibrozilGadiformesApolipoprotein B-48Lipoproteins, IDL